Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents | Zendy

Floyd R. Sallee | Zendy; Eva Kohegyi | Zendy; Joan Zhao | Zendy; Robert D. McQuade | Zendy; Kevin Cox | Zendy; Raymond Sanchez | Zendy; Alet van Beek | Zendy; Margaretta Nyilas | Zendy; William H. Carson | Zendy; Roger Kurlan | Zendy

Open Access

Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents

Author(s) -

Floyd R. Sallee,

Eva Kohegyi,

Joan Zhao,

Robert D. McQuade,

Kevin Cox,

Raymond Sanchez,

Alet van Beek,

Margaretta Nyilas,

William H. Carson,

Roger Kurlan

Publication year - 2017

Publication title -

journal of child and adolescent psychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.935

H-Index - 84

eISSN - 1557-8992

pISSN - 1044-5463

DOI - 10.1089/cap.2016.0026

Subject(s) - aripiprazole , placebo , tourette syndrome , randomized controlled trial , medicine , clinical endpoint , population , tics , randomization , adverse effect , placebo controlled study , psychology , psychiatry , pediatrics , double blind , schizophrenia (object oriented programming) , alternative medicine , environmental health , pathology

Aripiprazole modulates dopaminergic and serotonergic pathways that may play a role in the pathogenesis of Tourette's disorder (TD). This trial evaluated the efficacy and safety of oral aripiprazole in the suppression of tics in children and adolescents with TD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research